B.More Advances FDA Drug Trials using Psilocybin to Treat Alcoholism
70% of alcoholics relapse within a year of treatment. Could psilocybin change this?
A recent meta-analysis of the top six best-controlled studies found that patients were 59% more likely to abstain from alcohol use after completing psychedelic therapy. Why is it so effective? Essentially, psychedelics stimulate synaptic growth to “rewire” the brain and break bad habits.
A non-profit in New York called B.More is preparing to build on this research in a Phase 2/3 FDA trial, which will study psilocybin’s effect on alcohol use disorder (AUD).